
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio Inc is advancing its clinical pipeline with promising product candidates such as prulacabtagene leucel (prula-cel) and ADI-212, targeting both autoimmune diseases and oncology, with initial data expected for ADI-212 in metastatic castration-resistant prostate cancer in the latter half of 2026. The preliminary Phase 1 data suggesting meaningful efficacy of prula-cel in lupus nephritis (LN) and systemic lupus erythematosus (SLE) enhances its appeal, particularly as the company pursues additional autoimmune indications, which could lead to further upside. Additionally, by contracting third-party manufacturers for commercial-scale production, the company is effectively mitigating manufacturing risks, thereby strengthening its overall investment case.
Bears say
Adicet Bio faces significant financial challenges, projecting a net loss of $11.58 per share for 2026, which raises concerns about the company's economic viability. There are multiple risks compounding these concerns, including negative clinical data, regulatory approvals uncertainty, and potential setbacks in clinical development timelines, all of which could diminish market share and revenue prospects. Additionally, the lack of FDA approval for any Vδ1 gamma-delta T-cell therapies introduces heightened regulatory risks, potentially leading to further investment dilution and lowered expectations for commercial success.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares